NOV 19, 2017 2:02 PM PST

Expectation vs. Reality for Cancer Patients in Trials

WRITTEN BY: Xuan Pham

Image credit: Pixabay.com

Cancer patients participating in clinical trials may have their expectations set too high, say researchers. In particular, patients were keen to see their tumor shrink and some even expected a complete cure. While these scenarios would be ideal for everyone involved, the reality often proves to be more challenging.

Clinical trials are the gold standard by which all drugs, devices, or treatments must meet before being marketed to the public. Through several rigorous phases, a treatment must be proven safe and efficacious in human participants.
 
For any treatment to get to clinical trial is already a big deal – it means that the treatment has passed through the burden of research and development in the lab and in animal trials. This process alone can take as long as decades. So when a treatment is ready to be tested in people, it means there’s much evidence to hope that the treatment will work in people too.
 
Indeed, cancer patients appear to be counting on the research to pay off for them, understandably. In a study with 396 cancer patients who were considering to enter a Phase I clinical trial, researchers found that a large percentage expected positive results from the treatment. Specifically, nearly 43 percent predicted the tumor would shrink even before consulting with clinicians. And after consultation, patients’ hopes only increased, as 47 percent predicted tumor shrinkage.
 
Of note, the clinical trial available to the participants was a Phase I trial, which is designed to screen for safety. Essentially, this important step determines whether a treatment is safe in people, and at what dose do the side effects occur. Typically, this phase of the study is restricted to a small number of patients for whom standard therapy has not worked. Response rate is usually between 4 and 20 percent, while the median survival time for the enrolled participants is 6 months.
 
Nevertheless, it must be said that positive expectations can be great weapons against cancer.


"There is a positive message in this, which is that 84 percent of patients are willing to participate in phase I oncology studies after a discussion with clinical and nursing staff who lay out the conservative estimates of benefit and requirements of hospital visits. This is good for current and future patients and cancer medicine in general," said Udai Banerji from the NHS Foundation Trust and The Institute of Cancer Research, who led the study.
 
"The high percentage of patients expecting their tumors to shrink was a sobering finding. This creates a challenge for healthcare professionals to manage expectations but to do so without being patronizing or dismissing human hope," Banerji added. It’s a fine balance between encouraging patients to fight their disease and also offering them the appropriate information to guide their decisions, and perhaps these results underscore the need to improve for both doctors and patients.

Additional sources: Wiley press release via MNT

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
JUN 10, 2021
Cell & Molecular Biology
Does Lithium Prevent Colon Cancer?
JUN 10, 2021
Does Lithium Prevent Colon Cancer?
Researchers found that a drug used in the treatment of mental illness can promote the fitness of healthy gut stem cells, ...
JUN 11, 2021
Cancer
Man beats brain cancer with ketogenic diet
JUN 11, 2021
Man beats brain cancer with ketogenic diet
Glioblastoma brain cancer continues to be one of the most fatal cancers, responsible for approximately 15,000 death ever ...
AUG 12, 2021
Cancer
Promising Drug Target Identified for Deadly Ovarian Cancer
AUG 12, 2021
Promising Drug Target Identified for Deadly Ovarian Cancer
Scientists at the University of Alabama at Birmingham have identified a gene called DOT1L for its role in progressing th ...
AUG 13, 2021
Cancer
Ultrasound Triggers Immunotherapy to Destroy Tumors
AUG 13, 2021
Ultrasound Triggers Immunotherapy to Destroy Tumors
An immunotherapy engineered to be triggered by ultrasound beams significantly slows the growth of cancerous tumors in mi ...
SEP 09, 2021
Cancer
Can a Mole Fight Melanoma?
SEP 09, 2021
Can a Mole Fight Melanoma?
About 30% of melanoma cases arise from an existing nevus.  More commonly known as moles, Nevi are skin growths that ...
SEP 06, 2021
Drug Discovery & Development
Antibiotics Increase Colon Cancer Risk by 17%
SEP 06, 2021
Antibiotics Increase Colon Cancer Risk by 17%
People who take antibiotics are at an increased risk of developing colon cancer within five to ten years. The research w ...
Loading Comments...